Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial

AIM: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease‐modifying anti rheumatic drugs (csDMARDs) on patient‐reported outcomes in Chinese patients with RA and inadequate response to DMARDs...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhanguo, An, Yuan, Su, Houheng, Li, Xiangpei, Xu, Jianhua, Zheng, Yi, Li, Guiye, Kwok, Kenneth, Wang, Lisy, Wu, Qizhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817244/
https://www.ncbi.nlm.nih.gov/pubmed/29314645
http://dx.doi.org/10.1111/1756-185X.13244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817244/
https://www.ncbi.nlm.nih.gov/pubmed/29314645
http://dx.doi.org/10.1111/1756-185X.13244

Ejemplares similares